Needham, Massachusetts, United States, October 14, 2026
Mighty Therapeutics Inc. has reported significant commercial, clinical and research milestones across its portfolio of mitochondria-targeted therapies, highlighting continued progress in rare genetic diseases and age-related conditions. The company’s October 14, 2026, update focuses on the commercial performance of FORZINITY™ (elamipretide), its FDA-approved treatment for Barth syndrome, and advances in clinical development programs targeting dry age-related macular degeneration (AMD), POLG-related mitochondrial disease, Parkinson’s disease and fatty acid oxidation disorders. One year after FORZINITY received FDA accelerated approval, Mighty reported $17.5 million in cumulative gross revenue from its commercial soft launch through September 2026. The company also outlined plans to expand research, strengthen patient access and advance additional investigational candidates targeting mitochondrial dysfunction.
FORZINITY Commercial Launch Shows Continued Growth
Mighty Therapeutics reported that FORZINITY, approved by the U.S. Food and Drug Administration on September 19, 2025, continues to gain commercial momentum among eligible patients living with Barth syndrome, a rare, serious mitochondrial disease that affects muscle function and other aspects of health. The treatment is indicated to improve muscle strength in adult and pediatric patients weighing at least 30 kilograms and was granted accelerated approval based on improvement in knee extensor muscle strength, an intermediate clinical endpoint. From the commercial soft launch in December 2025 through September 2026, the company recorded $17.5 million in gross revenue, including $8.1 million during the third quarter of 2026. Mighty also received 60 patient enrollment forms and reported 48 unique prescribers. According to the company, more than 90% of covered lives across major U.S. health plans have access to reimbursement for the treatment. The company’s Mito Assist™ patient support program continues to help coordinate treatment access, education and assistance throughout the patient journey. These commercial developments demonstrate progress in establishing access to a therapy for a disease with historically limited treatment options. However, because FORZINITY received accelerated approval, continued approval may depend on verification and description of clinical benefit through confirmatory studies.
Clinical Pipeline Advances Across Rare Diseases
Mighty is expanding its clinical development efforts beyond Barth syndrome. Its fully enrolled Phase 3 ReNEW trial of elamipretide for dry age-related macular degeneration remains on track for topline results in the second half of 2027. The company has also reached preliminary agreement with the FDA on endpoint selection and protocol design and plans to initiate the Phase 2 ReBUILD study of bevemipretide eye drops by the end of 2026. In Barth syndrome, the global Phase 4 4TAZPower study is evaluating the efficacy, safety and pharmacokinetics of once-daily elamipretide in patients aged five years and older. Study sites have been initiated in Canada, Australia, Ireland and the United Kingdom. Mighty is also preparing a pharmacokinetic study to inform dosing for children weighing less than 30 kilograms, with the aim of supporting a potential supplemental BLA submission in 2027 for children weighing at least seven kilograms. For patients weighing less than seven kilograms, the company continues to provide access through an expanded access program. A planned patient registry will collect long-term real-world evidence that may help support future regulatory discussions and confirmation of clinical benefit. The company is additionally preparing for a potential pivotal study of elamipretide in POLG-related mitochondrial disease, with initiation anticipated in 2027. In its earlier-stage pipeline, Mighty is progressing systemic bevemipretide for Parkinson’s disease and MYTX-589 for Leigh syndrome and Friedreich’s ataxia. It has also initiated investigational new drug-enabling studies for MYTX-255, a candidate being developed for fatty acid oxidation disorders.
Advertisement
Funding and Research Support Future Development
To support commercial expansion and pipeline advancement, Mighty previously secured access to up to $150 million in financing, combining a credit facility with additional equity financing. The company expects this capital to support operations and development activities through projected cash-flow positivity in early 2029. Mighty is also collaborating with research organizations to strengthen its scientific programs, including work on a Parkinson’s disease mouse model with The POLG Foundation. Separately, a research team involving Mighty and the University of Washington was named a Milestone 2 Awardee in the XPRIZE Healthspan competition, supporting work toward evaluating elamipretide in older adults. Together, these milestones reflect Mighty Therapeutics’ strategy of developing treatments that target mitochondrial dysfunction, a biological mechanism implicated in several rare genetic and age-related disorders. Upcoming clinical readouts, confirmatory studies and regulatory discussions will be important in determining the future role of its investigational therapies. While the commercial progress of FORZINITY provides an established foundation, the broader pipeline remains dependent on clinical evidence and regulatory outcomes.
Source: Mighty Therapeutics press release
